Literature DB >> 20532625

Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats.

Alexandre Fornari1, Ernani Luis Rhoden, Cláudio G Zettler, Eduardo P Ribeiro, Claudia R Rhoden.   

Abstract

OBJECTIVE: The objective of the present study is to evaluate the histomorphometric characteristics of the prostate of rats submitted to chronic (long-time) treatment with doxazosin mesylate, finasteride and both substances combined.
MATERIALS AND METHODS: Four groups of eight rats each were selected for this study and treated with saline solution (control), doxazosin mesylate, finasteride and combination of the drugs, during 10 months. After this time, the prostate was removed, weighed and sent for histological analysis. Prostate sections were stained with Masson trichrome. With an image analyzer, the percentage of smooth muscle, collagen, epithelium, acinar lumen and interstitial space was measured. Also, the minimum, medium and maximum epithelial thickness, number of acini per field, mean acinar area and the presence of papillary projections were evaluated.
RESULTS: The mean prostate weight of rats treated with finasteride and combined treatment was lower when compared to the control group (P < 0.05). Prostate from rats treated with finasteride alone had a lower percentage of the epithelial component and a smaller minimum epithelial thickness than the control group (P < 0.05). The number of acini per field in the combined groups was higher than that observed in all other groups (P < 0.05). Also, rats of the finasteride and combined groups presented a reduced number of papillary projections when compared to the other groups (P < 0.05).
CONCLUSION: Our study clearly showed the effects of finasteride on prostate tissue, and from a histomorphometric perspective, it was not able to detect any advantage of the combined treatment over the use of finasteride alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20532625     DOI: 10.1007/s11255-010-9770-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  18 in total

1.  Two-drug therapy is best for symptomatic prostate enlargement: could a combination of doxazosin and finasteride change clinical practice?

Authors:  J M Fitzpatrick; R S Kirby
Journal:  BJU Int       Date:  2004-05       Impact factor: 5.588

Review 2.  Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.

Authors:  Natasha Kyprianou
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

3.  Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.

Authors:  L S Marks; A W Partin; G J Gormley; F J Dorey; E D Shery; J B Garris; E N Subong; E Stoner; J B deKernion
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

4.  Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.

Authors:  D T Glassman; J K Chon; A Borkowski; S C Jacobs; N Kyprianou
Journal:  Prostate       Date:  2001-01-01       Impact factor: 4.104

5.  Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate.

Authors:  A Erdem Canda; M Ugur Mungan; Osman Yilmaz; Kutsal Yorukoglu; Emre Tuzel; Ziya Kirkali
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

6.  Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Authors:  R Bruskewitz; C J Girman; J Fowler; O F Rigby; M Sullivan; R B Bracken; H A Fusilier; D Kozlowski; S D Kantor; E L Johnson; D Z Wang; J Waldstreicher
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

7.  Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.

Authors:  Tibet Erdoğru; M Akif Ciftcioglu; Ibrahim Emreoglu; Mustafa F Usta; Turker Koksal; Gülay Ozbilim; K Hakan Gulkesen; Mehmet Baykara
Journal:  Urol Int       Date:  2002       Impact factor: 2.089

8.  Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France.

Authors:  P P Sagnier; G MacFarlane; F Richard; H Botto; P Teillac; P Boyle
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Doxazosin reduces cell proliferation and increases collagen fibers in rat prostatic lobes.

Authors:  Luis A Justulin; Flavia K Delella; Sérgio L Felisbino
Journal:  Cell Tissue Res       Date:  2008-01-10       Impact factor: 5.249

10.  Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.

Authors:  S Dutkiewics
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.266

View more
  1 in total

1.  Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model.

Authors:  Selahattin Çalışkan; Muzaffer Oğuz Keleş; Metin İshak Öztürk; Musab Ali Kutluhan; Olgu Enis Tok; Feriha Ercan; Muhammet İhsan Karaman
Journal:  Turk J Urol       Date:  2017-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.